Accelerator Announces Latest Cohort of 10 New Health-Care Startups

We know that large, well-known companies such as Abbot, Medtronic, and Withings bring new digital health tech products to market. Small start-up companies with a new idea often lack sufficient resources to take those ideas all the way through design, development, testing, production, licensing and approvals, marketing, and distribution. Fortunately, institutional and venture capital-backed incubators and innovation centers such as Mass Digital Health and MedTech Innovator exist to support nascent technologies. The Cedars-Sinai Accelerator (CSA) is a such a program, created to help selected startup companies bring new healthcare technologies to the marketplace. The Cedars-Sinai Accelerator recently announced its latest selection of 10 health-tech startups. This group is the eighth CSA accelerator class.

Each business in the Cedars-Sinai Accelerator class receives a $100,000 investment. The program lasts for three months, during which startups have access to clinical experts in 11 medical care specialties and mentorship from top-rated healthcare professionals, executives, physicians, and researchers. The participants also have dedicated office areas in the Cedars-Sinai Innovation Space and access to Cedars-Sinai’s IT ream and information infrastructure. The selected startups also join Cedars-Sinai’s international network of healthcare entrepreneurs and investors and have an opportunity to pitch their innovation to investors, healthcare leaders, press, and others during a Demo Day.

Two of the health tech startups in this most recent class are Aevice Health and Luminare. Aevice Health is a Singapore-based company that has developed an Ai-powered wearable stethoscope that monitors and analyzes key biomarkers of respiratory health and chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) at home. Luminaire’s technology is a digital platform focused on early detection of sepsis. Detecting sepsis sooner increases the chance of saving lives by starting treatment plans for the medical emergency before the potentially fatal reaction to infection advances too far.

biomarkers
medical
healthcare
digital health
ai
venture capital
rated